CRSP
Crispr Therapeutics AG
NASDAQ: CRSP · HEALTHCARE · BIOTECHNOLOGY
$50.71
-2.59% today
Updated 2026-04-29
Market cap
$4.70B
P/E ratio
—
P/S ratio
1,340.31x
EPS (TTM)
$-6.47
Dividend yield
—
52W range
$33 – $78
Volume
2.0M
Crispr Therapeutics AG (CRSP) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-5.5%
Last 4 quarters
Revenue YoY growth
-97.5%
Most recent quarter
EPS YoY growth
-211.4%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+0.1%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
-0.9%
2025-08-04
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-17 | $-1.37 | -17.1% | $53.07 | $53.52 | +0.8% |
| 2025-11-05 | $-1.17 | +10.7% | $56.41 | $56.61 | +0.4% |
| 2025-08-04 | $-1.29 | +7.9% | $56.09 | $55.59 | -0.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-1.17 | $-1.37 | -17.1% | $864000.00 | -97.5% |
| 2025-09-30 | $-1.31 | $-1.17 | +10.7% | $889000.00 | +47.7% |
| 2025-06-30 | $-1.40 | $-1.29 | +7.9% | $892000.00 | +72.5% |
| 2025-03-31 | $-1.28 | $-1.58 | -23.4% | $865000.00 | +71.6% |
| 2024-12-31 | $-1.19 | $-0.44 | +62.9% | $35.00M | -82.5% |
| 2024-09-30 | $-1.40 | $-1.01 | +27.9% | $602000.00 | — |
| 2024-06-30 | $-1.52 | $-1.49 | +2.0% | $517000.00 | -99.3% |
| 2024-03-31 | $-1.33 | $-1.43 | -7.5% | $504000.00 | — |
| 2023-12-31 | $-0.07 | $1.10 | +1671.4% | $200.00M | — |
| 2023-09-30 | $-1.95 | $-1.41 | +27.7% | — | — |
| 2023-06-30 | $-2.12 | $-0.98 | +53.8% | $70.00M | — |
Frequently asked questions
Has Crispr Therapeutics AG beaten earnings estimates?
Crispr Therapeutics AG has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -5.5% over the last 4 quarters.
How does CRSP stock react to earnings?
CRSP stock has moved an average of +0.1% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is Crispr Therapeutics AG's revenue growth rate?
Crispr Therapeutics AG reported year-over-year revenue growth of -97.5% in its most recent quarter, with EPS growing -211.4% year-over-year.